U.S. markets close in 3 hours 30 minutes

Humanigen, Inc. (HGEN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.3800+0.0089 (+2.40%)
As of 12:29PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close0.3711
Bid0.3790 x 800
Ask0.3798 x 2200
Day's Range0.3658 - 0.3820
52 Week Range0.3500 - 18.2200
Avg. Volume7,857,867
Market Cap26.841M
Beta (5Y Monthly)-1.22
PE Ratio (TTM)N/A
EPS (TTM)-3.1140
Earnings DateNov 10, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for HGEN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Humanigen, Inc.
    Market Update: CENT, EBAY, PFE, VMC, RKTStocks were mostly higher on Thursday morning amid more signs of moderating inflation. The Labor Department said that its producer price index for final demand fell 0.5% in July, down from a 1.0% increase in June. The reading was the first negative number since April 2020 and below the Reuters consensus forecast, which called for an increase of 0.2%. The Dow rose 0.5%, the S&P rose 0.4%, and the Nasdaq was flat. Crude oil rose 1.5% to $93.50 per barrel, while gold rose $8 to $1806 per ounce.
    Fair Value
    Economic Moat
    23 hours agoArgus Research
View more
  • Newsfile

    Humanigen Implements Strategic Realignment of Pipeline and Resources to Achieve Key Clinical Milestones

    Short Hills, New Jersey--(Newsfile Corp. - July 26, 2022) - Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab, a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today announced a strategic realignment of its pipeline and resources to achieve key clinical milestones. The Company plans to accelerate the development of lenzilumab in chronic myelomonocytic leukemia ("CMML"), a

  • American City Business Journals

    Martin Shkreli's onetime company loses 80% of value as Covid drug trial fails

    The company, whose history includes pharma bad-boy Martin Shkreli and a trip into Chapter 11 bankruptcy, had hoped the National Institutes of Health-sponsored study would help it win FDA emergency use authorization.

  • TipRanks

    Humanigen Stock: Why It Crashed and Where It’s Headed

    Covid-19 opened up plenty of opportunities for smaller pharma companies to make their mark, by developing either vaccines or treatments. But it’s no easy task getting a product approved, and many have been unable to get their candidates across the finish line. The latest victim in the space appears to be Humanigen (HGEN). Shares took a proper thrashing in Wednesday’s session, after the company disclosed that its experimental antibody Lenzilumab failed to make the grade as a treatment for hospita